SGLT-2 Inhibitors

SGLT-2 inhibitors are a breakthrough class of medications that are used to treat type 2 diabetes by targeting a specific protein in the kidneys These inhibitors work by blocking the reabsorption of glucose allowing excess glucose to be excreted in the urine By reducing blood glucose levels SGLT-2 inhibitors help to improve glycemic control and lower the risk of cardiovascular events Additionally these medications have been shown to promote weight loss and reduce blood pressure With their unique mechanism of action and multiple benefits SGLT-2 inhibitors have become an important tool in the management of type 2 diabetes

Catalog Number	Chemical Name	CAS #	Price
EI-0374	Bexgliflozin (EGT1442)	1118567-05-7	Online Inquiry
EI-0503	Canagliflogin	842133-18-0	Online Inquiry
EI-0709	Dapagliflozin	461432-26-8	Online Inquiry
EI-0806	Empagliflozin	864070-44-0	Online Inquiry
EI-0832	Ertugliflozin	1210344-57-2	Online Inquiry
EI-1225	Ipragliflozin	761423-87-4	Online Inquiry
EI-1377	LX-4211	1018899-04-1	Online Inquiry
EI-1866	Remogliflozin	329045-45-6	Online Inquiry
EI-2187	Tofogliflozin	903565-83-3	Online Inquiry

Application

SGLT-2 inhibitors are a widely used class of medications that have diverse applications in the field of medicine One of their primary applications is in the management of type 2 diabetes By inhibiting the SGLT-2 transporter in the kidneys these inhibitors prevent the reabsorption of glucose leading to an increase in urinary glucose excretion and a reduction in blood glucose levels This mechanism helps to control blood sugar levels and improve glycemic control in patients with diabetes

Beyond their role in diabetes management SGLT-2 inhibitors have also shown promising results in the treatment of heart failure These medications have been found to reduce the risk of cardiovascular events and hospitalizations for heart failure in patients with or without diabetes By improving cardiac function and reducing fluid overload SGLT-2 inhibitors provide an additional therapeutic option for individuals with heart failure

Furthermore SGLT-2 inhibitors have been investigated for their potential benefits in chronic kidney disease These medications have shown renoprotective effects including a reduction in albuminuria and a slower decline in estimated glomerular filtration rate (eGFR) This makes them a valuable tool in managing kidney complications associated with diabetes and other conditions

In summary SGLT-2 inhibitors have a wide range of applications in the field of medicine including the management of type 2 diabetes treatment of heart failure and potential benefits in chronic kidney disease These medications offer effective and innovative therapeutic options for patients with these conditions

Please note that all services are for research use only. Not intended for any clinical use.

SGLT-2 Inhibitors